Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

202466 citationsJournal Articlehybrid Open Access

Authors

Both doses of deuruxolitinib were effective for hair regrowth. Patient satisfaction aligned with hair growth.

Good health and well-being

Published in: Journal of the American Academy of Dermatology

Volume 91, Issue 5, pp. 880-888

Field-Weighted Citation Impact: 34.99